KEEP BUT DO NOT DISPLAY

Sanofi Withdrawing NDA for Lixisenatide  Sanofi announced they are withdrawing their New Drug Application (NDA) for their once-daily GLP-1 lixisenatide from the FDA. The combination of lixisenatide and Lantus® (basal insulin), the investigational LixiLan fixed-ratio product, remains on schedule to enter into phase 3 in the first half of 2014. 

The benefits of acarbose on cardiovascular risk may be related to its stimulation of GLP-1 secretion. Blood was drawn from 24 subjects with drug-naïve T2D at 0 and 120 min following a standard mixed meal to measure active GLP-1, NO and NOS. The CIMT was measured prior to and following …

Overweight shoppers who got a flier with health-related information as they entered a grocery store spent about $1.40 on unhealthy snacks, compared with $4.80 spent by those who got a comparison flier without the cues, researchers reported. International Journal of Obesity Sept, 2013 

Diabetes patients whose full-body MRIs showed "vascular changes" had a 20% risk of heart attack or stroke at three years and a 35% risk at six years compared with those whose results did not reveal changes, a study indicated. Scientists found that scanning the body with magnetic resonance imaging (MRI) …

Urine Testing Can Screen for Cognitive Decline  See this week’s Item #2.

Peter Liu of the Los Angeles Biomedical Research Institute and colleagues at the University of Sydney checked insulin sensitivity in 19 non-diabetic men who slept about 6 hours a night during the workweek, but 10 hours on weekend nights. "By extending sleep to 10 hours a night versus 6 hours …

The average French competitor in the Tour de France lives about 6 years longer than their non-competitive French age-matched countrymen, Xavier Jouven, MD, a cardiologist at Hopital Europeen Georges-Pompidou, Paris, said at the European Society of Cardiology meeting. "We found a substantially and significantly lower mortality in French participants in …

The U.S. will continue to lead the trend of growing waistlines across the developed world, a new study predicted. Altogether, eight leading developed countries and Brazil will see an increase in obesity cases from about 167 million last year to 213 million by 2022. Brazil will be second to the …

Family History Not Obesity Greatest Risk Factor  See this week’s Item #1.

A new study in Diabetes Care revealed hypertension, QT prolongation and hypokalemia were common in diabetes patients with severe hypoglycemia, possibly shedding light on how low blood glucose levels result in fatal arrhythmia and death. Type 1 diabetes patients were less likely than those with type 2 diabetes to have …